news

Guangshengtang, which was listed twice in three days, issued an announcement on abnormal stock trading fluctuations on August 14, stating that the company's closing price increase deviation value for three consecutive trading days from August 12 to August 14, 2024 exceeded 30%. According to regulations, this is a case of abnormal stock trading fluctuations.

The company's innovative hepatitis B treatment drug GST-HG141 obtained domestic clinical trial approval in November 2019 and is currently in the Phase II clinical stage. The data unblinding of clinical research results has been completed. The R&D cycle of innovative drugs is long, the investment is large, the risk is high, and it is easily affected by multiple factors such as technology, approval, and policy. There is a risk that the results of clinical research will not meet expectations or even fail, and there is uncertainty as to whether it can be approved in the future.

According to the data on the website of China Securities Index Co., Ltd., the latest rolling P/E ratio of the pharmaceutical manufacturing industry classified by the China Association of Public Companies is 24.44. Due to the negative audited net profit of the company in 2023, the company's stock P/E ratio is negative, which deviates greatly from the industry average. The company's stock price has risen sharply in a short period of time, but the company's fundamentals have not changed significantly. There may be irrational speculation and other situations, and there may be a risk of a decline in stock prices after a sharp rise.

The company has been in a loss-making state from 2021 to the first quarter of 2024, and the net profit attributable to shareholders of listed companies was -34.8866 million yuan, -127 million yuan, -349 million yuan, and -14.6427 million yuan, respectively.

The company has not found any undisclosed material information reported by the public media recently that may or has had a significant impact on the company's stock trading price. There have been no major changes in the company's operating conditions and internal and external operating environment recently.